CrimsonCanary announce the availability of Polo like kinase competitor pipeline

CrimsonCanary and KinaseCentral are pleased to announce the availability of its first report for sale:

Polo Like Kinases, August 2008
Table of Contents
Buy Report, $600
For questions about CrimsonCanary reports, to suggest a target for analysis or to discuss custom client based work please email: info@crimsoncanary.com

Phase II nimotuzumab data supports continued development

YM Biosciences have released Phase II data that show its EFGR antibody nimotuzumab to be effective in patients with irinotecan–refractory, metastatic colorectal cancer.

Imatinib in connective tissue diseases

Three papers in this months Arthritis and Rheumatism discuss Imatinib in connective tissue diseases:

Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease
Imatinib mesylate treatment of nephrogenic systemic fibrosis
Is imatinib mesylate a promising drug in systemic sclerosis?

Amgen publish series of c-Kit inhibitors

Amgen have published the discovery of amido-benzisoxazole c-Kit Inhibitor.

Researchers outline methodology for rational redesign of kinase inhibitors

Researchers at Rice University outline methodologies for the rational redesign of kinase inhibitors, aiming to turn them into more selective ligands.